Home
HUYA Bioscience

HUYA Bioscience Market Share Analysis for June 2026

HUYA Bioscience International is the leader in globalizing China’s biopharma innovation. With eight offices staffed with dedicated scientists throughout China, the Company has amassed the largest compound portfolio covering all major therapeutic areas.

Health > Biotechnology and Pharmaceuticals

Domainhuyabio.com

Year Founded2004

Employees51 - 200

Annual Revenue$15M - $25M

HUYA Bioscience

HUYA Bioscience (including company regionals)

huyabio.com

See more website traffic and engagement information

HUYA Bioscience Revenue up to June 2026 is 15M - 25M

revenue generated by HUYA Bioscience top domains

HUYA Bioscience top domains revenue over 3 years

Revenue for HUYA Bioscience top domains

huyabio.com15M - 25M

See more with Sales Intelligence

Total visits to HUYA Bioscience's top domains

Understand HUYA Bioscience market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

huyabio.com2.4K

See more with Sales Intelligence

Avg. visit duration in HUYA Bioscience's top domains

Analyze HUYA Bioscience engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

huyabio.com00:00:43

See more with Sales Intelligence

Avg. pageviews on HUYA Bioscience's top domains

See how HUYA Bioscience keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

huyabio.com1.96

See more with Sales Intelligence

HUYA Bioscience top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by HUYA Bioscience

These are the website technologies, by industry, used by HUYA Bioscience top domains

Widget (3)

Twemoji

Content Management System (2)

WordPress

Mobile (2)

Meta Viewport

Advertising (1)

PubMatic

More Technologies

8

See all

News & Signals from HUYA Bioscience

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsHUYABIO International launched patient data for HBI-3000 on Apr 24th '25.SAN DIEGO, April 24, 2025 /PRNewswire/ - HUYABIO International today announced the presentation of new patient data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a unique mechanism limiting QT prolongation and risk of inducing lethal arrhythmias.

NewsHUYABIO International hires Paul Spreen as Chief Business Officer.Huyabio International has appointed Paul Spreen as Chief Business Officer.

NewsHUYABIO International partners with Shanghai Pharma.Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO, said, “HUYABIO International is delighted to partner with Shanghai Pharmaceuticals for a therapeutic mechanism that promises broad synergy across treatments for many tumor types.